Do China Start-ups Differ From The West?
This article was originally published in PharmAsia News
During the annual ChinaBio conference in Shanghai, four top start ups – Ascletis, Aslan, BeiGene and Hua Medicine – discuss how their strategies in China differ from the traditional U.S. biotech model.
You may also be interested in...
Talk to any big pharma business development executive about dealmaking trends for more than 15 minutes and the word out-licensing is bound to crop up. But are major drugmakers moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing? An analysis by IN VIVO suggests yes – but with qualifications.
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2